Literature DB >> 10841143

Lung cancer.

P C Hoffman1, A M Mauer, E E Vokes.   

Abstract

Lung cancer remains a major worldwide health problem, accounting for more than a sixth of cancer deaths. The proportion of cancers that are adenocarcinomas is increasing in North America and to some degree in Europe, leading to a changing clinical picture characterised by early development of metastases. Newer diagnostic techniques have allowed for more accurate tumour staging and treatment planning. In patients with non-small-cell cancer, surgical resection offers substantial cure rates in early-stage cases. Combined chemotherapy plus radiation therapy has clearly improved the treatment results for patients with locally advanced cancers, and patients with metastatic disease are now candidates for newer chemotherapy regimens with more favourable results than in the past. Small-cell lung cancer is highly responsive to chemotherapy, and recent advances in radiation therapy have improved the prospects for long survival. New techniques for screening, and innovative approaches to both local and systemic treatment offer hope for substantial progress against this disease in the near future.

Entities:  

Mesh:

Year:  2000        PMID: 10841143     DOI: 10.1016/S0140-6736(00)82038-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  237 in total

Review 1.  18-Fluorodeoxyglucose positron emission tomography (FDG-PET) and the staging of early lung cancer.

Authors:  G Laking; P Price
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

2.  Requirements for clinical PET: comparisons within Europe.

Authors:  Michael Bedford; Michael N Maisey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

Review 3.  Nitric oxide and cancer therapy: the emperor has NO clothes.

Authors:  Jason R Hickok; Douglas D Thomas
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 4.  Epigenetics of lung cancer.

Authors:  Scott M Langevin; Robert A Kratzke; Karl T Kelsey
Journal:  Transl Res       Date:  2014-03-12       Impact factor: 7.012

5.  Association between the CpG island methylator phenotype and its prognostic significance in primary pulmonary adenocarcinoma.

Authors:  Young Wha Koh; Sung-Min Chun; Young-Soo Park; Joon Seon Song; Geon Kook Lee; Shin Kwang Khang; Se Jin Jang
Journal:  Tumour Biol       Date:  2016-02-11

6.  Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis.

Authors:  Fengwei Tan; Ying Jiang; Nan Sun; Zhaoli Chen; Yongzhuang Lv; Kang Shao; Ning Li; Bin Qiu; Yibo Gao; Baozhong Li; Xiaogang Tan; Fang Zhou; Zhen Wang; Dapeng Ding; Jiwen Wang; Jian Sun; Jie Hang; Susheng Shi; Xiaoli Feng; Fuchu He; Jie He
Journal:  Mol Cell Proteomics       Date:  2011-11-07       Impact factor: 5.911

7.  Using protein microarray as a diagnostic assay for non-small cell lung cancer.

Authors:  Li Zhong; Giovanna E Hidalgo; Arnold J Stromberg; Nada H Khattar; James R Jett; Edward A Hirschowitz
Journal:  Am J Respir Crit Care Med       Date:  2005-08-18       Impact factor: 21.405

8.  Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo.

Authors:  Tripti Singh; Ram Prasad; Santosh K Katiyar
Journal:  Epigenetics       Date:  2012-12-05       Impact factor: 4.528

9.  Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer.

Authors:  Justin D Blasberg; Harvey I Pass; Chandra M Goparaju; Raja M Flores; Suzie Lee; Jessica S Donington
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

10.  Curcumin suppresses proliferation and invasion in non-small cell lung cancer by modulation of MTA1-mediated Wnt/β-catenin pathway.

Authors:  Yimin Lu; Changjiang Wei; Zhaoqing Xi
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-06-18       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.